Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nimodipine - Acasti Pharma

Next Previous
Drug Profile

Nimodipine - Acasti Pharma

Alternative Names: GTX 104; Nimodipine intravenous - Acasti Pharma

Latest Information Update: 06 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Grace Therapeutics
  • Developer Acasti Pharma
  • Class Antihaemorrhagics; Antihypertensives; Dihydropyridines; Esters; Small molecules
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Subarachnoid haemorrhage
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Subarachnoid haemorrhage

Most Recent Events

  • 04 Oct 2023 Phase-III clinical trials in Subarachnoid haemorrhage in USA (IV) (NCT05995405)
  • 28 Aug 2023 No recent reports of development identified for clinical-Phase-Unknown development in Subarachnoid-haemorrhage in USA (IV, Infusion)
  • 07 Jul 2023 Grace Therapeutics plans the phase III STRIVE-ON trial for Subarachnoid haemorrhage in USA (IV, Infusion) in the fourth quarter of 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top